Results of accelerated partial breast irradiation in patients not suitable for external beam irradiation stratified by GEC-ESTRO, ASTRO, and ABS guidelines

PURPOSE: This study aims to review the outcome of an institution in multicatheter/interstitial accelerated partial breast irradiation (MC-APBI) for treatment of patients with breast cancer, either with strong criteria for APBI or unable to be treated with whole-breast irradiation. The outcomes were also stratified by the American Society for Radiation Oncology, American Brachytherapy Society, and Groupe European de Curietherapie-European Society for Therapeutic Radiology and Oncology patient selection criteria. METHODS: The study includes 118 patients and 120 MC-APBI treatments, treated in a single tertiary center, between November 2003 and August 2016. The analysis is focused on the clinical baseline characteristics, local control, relapse-free survival, disease-specific survival (DSS), and overall survival. RESULTS: In accordance to the American Society for Radiation Oncology, American Brachytherapy Society, and Groupe European de Curietherapie-European Society for Therapeutic Radiology and Oncology, 17.1% were "unsuitable,'' 19.2% were "unacceptable,'' and 19.5% were "high risk,'' respectively. The main reasons why high-risk patients were submitted to MC-APBI were as follows: cardiopathy (n = 7), social difficulties (n = 4), and mobility limitations (n = 4). At the median followup period of 86.5 months, ipsilateral breast tumor recurrence was observed in one (0.8%) patient. The 3-year and 5-year relapse-free survival were 100% and 99.1%, respectively. DSS was 100%. CONCLUSIONS: This study demonstrated excellent control rates, DFS, and DSS of MC-APBI, rendering APBI as an excellent treatment for patients with breast cancer, even those who are not necessarily eligible for this treatment approach. The selection criteria for ABPI diverge according to different guidelines and are based on studies with discrepancies, making extremely possible that these recommendations could be changed. (C) 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.